Published on Oct 25, 2023 at 7:01 p.m.
PARIS (Agefi-Dow Jones)–The biotechnology company Valneva announced on Wednesday that it had submitted an authorization request for its chikungunya vaccine to European health authorities.
The European Medicines Agency (EMA) has agreed to examine this application in an accelerated manner due to the “major interest for public health” and the “therapeutic innovation” represented by this experimental vaccine, added the laboratory French.
The American marketing application already benefits from priority review by the Food and Drugs Administration (FDA), which must make its decision by the end of November.
If approved, this vaccine would become the first against chikungunya.
The global market for vaccines against this viral disease transmitted by Aedes mosquitoes was expected to exceed $500 million per year by 2032.
-Thomas Varela, Agefi-Dow Jones; +33 (0)1 41 27 47 99; [email protected] ed: LBO
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
October 25, 2023 1:01 p.m. ET (17:01 GMT)
Which stocks to buy?
Making the best investments requires detailed knowledge of the markets, their mechanisms, the economy and involves delving into the heart of the strategy of each listed company. The Investir editorial team does it for you and provides its subscribers with advice on more than 800 stocks. Benefit from their buy, speculative buy, spread or sell recommendations by subscribing to Investir.
I discover the offers